Cargando…

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)

BACKGROUND: Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab + pertuzumab plus chemotherapy regimens for pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yuanjia, Xiang, Hongyu, Xin, Ling, Duan, Xuening, Liu, Yinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771321/ https://www.ncbi.nlm.nih.gov/pubmed/36535009 http://dx.doi.org/10.1097/CM9.0000000000002197

Ejemplares similares

The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012)
por: Li, Yijun, et al.
Publicado: (2023)

Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
por: Chen, Heyan, et al.
Publicado: (2023)

Clinical characteristics and clinicopathological correlations of bilateral breast cancer in China: A multicenter study from Chinese Society of Breast Surgery (CSBrS-006)
por: Li, Xuelu, et al.
Publicado: (2021)

Clinical practice guideline for breast fibroadenoma: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Peng, Yuan, et al.
Publicado: (2021)

Clinical practice guidelines for intraductal papilloma: Chinese Society of breast surgery (CSBrS) practice guidelines 2021
por: Wu, Di, et al.
Publicado: (2021)

Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002)
por: Zheng, Ang, et al.
Publicado: (2021)

Survival in Breast Cancer Patients with Bone Metastasis: A Multicenter Real-World Study on the Prognostic Impact of Intensive Postoperative Bone Scan after Initial Diagnosis of Breast Cancer (CSBrS-023)
por: Yang, Liu, et al.
Publicado: (2022)

A retrospective clinical study of patients with pregnancy-associated breast cancer among multiple centers in China (CSBrS-008)
por: Jin, Yu-Chun, et al.
Publicado: (2021)

Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Zheng, Ang, et al.
Publicado: (2021)

A multi-center investigation of breast-conserving surgery based on data from the Chinese Society of Breast Surgery (CSBrS-005)
por: Yu, Li-Xiang, et al.
Publicado: (2020)

Clinical practice guidelines for post-mastectomy breast reconstruction: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Li, Yan-Shuang, et al.
Publicado: (2021)

Clinical practice guidelines for pregnancy-associated breast cancer: Chinese society of breast surgery (CSBrS) practice guidelines 2021
por: Chen, Qing, et al.
Publicado: (2021)

Clinical practice guidelines for pre-operative evaluation of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Zheng, Chao, et al.
Publicado: (2021)

Clinical practice guideline for diagnosis and treatment of hyperplasia of the mammary glands: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Ma, Wei, et al.
Publicado: (2021)

Clinical practice guidelines for visualized percutaneous breast tissue clips: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Chen, Wu-Zhen, et al.
Publicado: (2021)

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Liu, Miao, et al.
Publicado: (2021)

Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022
por: Ma, Li, et al.
Publicado: (2023)

Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Wang, Fei, et al.
Publicado: (2021)

Clinical practice guidelines for ultrasound-guided vacuum-assisted breast biopsy: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Li, Si-Jie, et al.
Publicado: (2021)

Clinical practice guidelines for diagnosis and treatment of patients with non-puerperal mastitis: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Zhou, Fei, et al.
Publicado: (2021)

Clinical practice guidelines for endoscopic breast surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Tang, Peng, et al.
Publicado: (2021)

Clinical practice guidelines for multigene assays in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Zhu, Jiu-Jun, et al.
Publicado: (2021)

Clinical practice guidelines for ultrasound-guided breast lesions and lymph nodes biopsy: Chinese society of breast surgery (CSBrS) practice guidelines 2021
por: Ma, Jin-Fei, et al.
Publicado: (2021)

Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Xie, Fei, et al.
Publicado: (2021)

Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Ye, Jing-Ming, et al.
Publicado: (2021)

Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
por: Chen, Kai, et al.
Publicado: (2021)

Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China: a multicenter, single-arm, open validation trial (CSBrS-024)
por: Qu, Fengjiang, et al.
Publicado: (2022)

Multi-center investigation of breast reconstruction after mastectomy from Chinese Society of Breast Surgery: A survey based on 31 tertiary hospitals (CSBrS-004)
por: Xu, Feng, et al.
Publicado: (2021)

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
por: Xin, Ling, et al.
Publicado: (2022)

Analysis of sentinel lymph node biopsy and non-sentinel lymph node metastasis in invasive ductal and invasive lobular breast cancer: a nationwide cross-sectional study (CSBrS-001)
por: Zhang, Juliang, et al.
Publicado: (2021)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
por: Li, Jiayi, et al.
Publicado: (2022)

Investigation of the current situation of nipple-sparing mastectomy: a large multicenter study in China (CSBrs-003)
por: Zhu, Li, et al.
Publicado: (2021)

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
por: Xu, Ling, et al.
Publicado: (2017)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
por: Xu, Ling, et al.
Publicado: (2018)

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
por: Guan, Dandan, et al.
Publicado: (2022)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Phase Equilibria in Ternary System CsBr-AgBr-InBr(3)
por: Kamilov, Rustam K., et al.
Publicado: (2023)

Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
por: Zhang, Mengmeng, et al.
Publicado: (2020)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8d77m0akqv9187gltlrc76ah86